Inhibrx Gross Profit from 2010 to 2024

INBX Stock

USD 14.08 0.10 0.72%

Inhibrx Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2024. Gross Profit is the profit Inhibrx makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2018-03-31

Previous Quarter

-360 K

Current Value

-375 K

Quarterly Volatility

6.1 M

Covid

Check Inhibrx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inhibrx's main balance sheet or income statement drivers, such as Interest Expense of 33.4 M, Minority Interest of 0.0 or Tax Provision of 2.6 K, as well as many indicators such as Price To Sales Ratio of 1 K, Dividend Yield of 0.0021 or PTB Ratio of 43.23. Inhibrx financial statements analysis is a perfect complement when working with Inhibrx Valuation or Volatility modules.

Check out the analysis of Inhibrx Correlation against competitors.

For more information on how to buy Inhibrx Stock please use our How to Invest in Inhibrx guide.

Latest Inhibrx's Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Inhibrx over the last few years. Gross profit is a required income statement account that reflects total revenue of Inhibrx minus its cost of goods sold. It is profit before Inhibrx operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Inhibrx's Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inhibrx's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (107.99 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Inhibrx Gross Profit Regression Statistics

	Arithmetic Mean	(12,125,903)
	Geometric Mean	9,769,578
	Coefficient Of Variation	(113.71)
	Mean Deviation	11,198,529
	Median	(17,560,000)
	Standard Deviation	13,788,547
	Sample Variance	190.1T
	Range	51.6M
	R-Value	0.55
	Mean Square Error	143T
	R-Squared	0.30
	Significance	0.03
	Slope	1,693,008
	Total Sum of Squares	2661.7T

Inhibrx Gross Profit History

	2024	639.5 K
	2023	609 K
	2022	2.2 M
	2021	7.1 M
	2020	12.8 M
	2019	-38.8 M
	2018	-26 M

Other Fundumenentals of Inhibrx

Gross Profit Margin

Inhibrx Gross Profit component correlations

	Net Tangible Assets	Retained Earnings	Accounts Payable	Total Current Assets	Property Plant Equipment	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Long Term Debt	Net Receivables	Total Liab	Net Invested Capital	Short Long Term Debt	Net Working Capital	Short Term Debt	Deferred Long Term Liab	Capital Stock	Common Stock	Long Term Debt Total	Capital Surpluse
Net Tangible Assets		-0.72	0.65	0.81	0.14	0.81	0.98	-0.71	-0.94	0.68	-0.02	0.5	0.84	-0.59	0.82	-0.78	-0.49	0.91	0.91	0.67	0.63
Retained Earnings	-0.72		-0.63	-0.97	-0.17	-0.97	-0.7	0.57	0.76	-0.97	0.26	-0.87	-0.94	0.75	-0.96	0.59	0.81	-0.83	-0.83	-0.97	-0.9
Accounts Payable	0.65	-0.63		0.69	0.68	0.71	0.76	-0.3	-0.85	0.56	-0.2	0.6	0.66	-0.72	0.68	-0.82	-0.3	0.71	0.71	0.5	0.52
Total Current Assets	0.81	-0.97	0.69		0.18	1.0	0.81	-0.62	-0.85	0.97	-0.36	0.86	0.99	-0.76	1.0	-0.71	-0.72	0.86	0.86	0.96	0.9
Property Plant Equipment	0.14	-0.17	0.68	0.18		0.21	0.28	0.46	-0.38	0.07	-0.12	0.21	0.1	-0.68	0.17	-0.63	0.06	0.11	0.11	-0.03	0.0
Total Assets	0.81	-0.97	0.71	1.0	0.21		0.81	-0.6	-0.86	0.97	-0.36	0.87	0.99	-0.78	1.0	-0.73	-0.72	0.85	0.85	0.95	0.89
Total Stockholder Equity	0.98	-0.7	0.76	0.81	0.28	0.81		-0.65	-0.98	0.67	-0.08	0.53	0.83	-0.65	0.82	-0.87	-0.41	0.9	0.9	0.63	0.62
Current Deferred Revenue	-0.71	0.57	-0.3	-0.62	0.46	-0.6	-0.65		0.59	-0.59	-0.08	-0.39	-0.67	0.04	-0.64	0.27	0.47	-0.76	-0.76	-0.64	-0.61
Net Debt	-0.94	0.76	-0.85	-0.85	-0.38	-0.86	-0.98	0.59		-0.72	0.16	-0.62	-0.87	0.73	-0.86	0.89	0.45	-0.91	-0.91	-0.68	-0.67
Long Term Debt	0.68	-0.97	0.56	0.97	0.07	0.97	0.67	-0.59	-0.72		-0.43	0.9	0.96	-0.71	0.97	-0.59	-0.75	0.76	0.76	0.99	0.93
Net Receivables	-0.02	0.26	-0.2	-0.36	-0.12	-0.36	-0.08	-0.08	0.16	-0.43		-0.42	-0.38	0.33	-0.38	0.31	0.15	0.08	0.08	-0.38	-0.28
Total Liab	0.5	-0.87	0.6	0.86	0.21	0.87	0.53	-0.39	-0.62	0.9	-0.42		0.83	-0.77	0.86	-0.51	-0.49	0.69	0.69	0.87	0.95
Net Invested Capital	0.84	-0.94	0.66	0.99	0.1	0.99	0.83	-0.67	-0.87	0.96	-0.38	0.83		-0.72	0.99	-0.7	-0.69	0.87	0.87	0.95	0.89
Short Long Term Debt	-0.59	0.75	-0.72	-0.76	-0.68	-0.78	-0.65	0.04	0.73	-0.71	0.33	-0.77	-0.72		-0.76	0.81	0.39	-0.6	-0.6	-0.63	-0.67
Net Working Capital	0.82	-0.96	0.68	1.0	0.17	1.0	0.82	-0.64	-0.86	0.97	-0.38	0.86	0.99	-0.76		-0.73	-0.69	0.86	0.86	0.95	0.9
Short Term Debt	-0.78	0.59	-0.82	-0.71	-0.63	-0.73	-0.87	0.27	0.89	-0.59	0.31	-0.51	-0.7	0.81	-0.73		0.25	-0.65	-0.65	-0.5	-0.47
Deferred Long Term Liab	-0.49	0.81	-0.3	-0.72	0.06	-0.72	-0.41	0.47	0.45	-0.75	0.15	-0.49	-0.69	0.39	-0.69	0.25		-0.54	-0.54	-0.79	-0.56
Capital Stock	0.91	-0.83	0.71	0.86	0.11	0.85	0.9	-0.76	-0.91	0.76	0.08	0.69	0.87	-0.6	0.86	-0.65	-0.54		1.0	0.76	0.81
Common Stock	0.91	-0.83	0.71	0.86	0.11	0.85	0.9	-0.76	-0.91	0.76	0.08	0.69	0.87	-0.6	0.86	-0.65	-0.54	1.0		0.76	0.81
Long Term Debt Total	0.67	-0.97	0.5	0.96	-0.03	0.95	0.63	-0.64	-0.68	0.99	-0.38	0.87	0.95	-0.63	0.95	-0.5	-0.79	0.76	0.76		0.93
Capital Surpluse	0.63	-0.9	0.52	0.9	0.0	0.89	0.62	-0.61	-0.67	0.93	-0.28	0.95	0.89	-0.67	0.9	-0.47	-0.56	0.81	0.81	0.93

Click cells to compare fundamentals

About Inhibrx Financial Statements

Inhibrx investors use historical fundamental indicators, such as Inhibrx's Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Inhibrx. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	609 K	639.5 K
Gross Profit Margin	0.34	0.36

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Inhibrx Stock Analysis

When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC